Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 12, 2022--
The "Sinusitis - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Sinusitis - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sinusitis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Sinusitis pipeline landscape is provided which includes the disease overview and Sinusitis treatment guidelines. The assessment part of the report embraces, in depth Sinusitis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Sinusitis Emerging Drugs Chapters
This segment of the Sinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sinusitis Emerging DrugsGLS-1200: GeneOne Life Science
GLS-1200 nasal spray stimulates multiple bitter taste receptors (TAS2Rs) on ciliated nasal epithelial cells to produce nitric oxide as part of the innate immune system. Nitric oxide has generalized anti-microbial activity in the upper respiratory tract. Currently, it is in Phase II stage of clinical trial evaluation to treat chronic Sinusitis.
LYR-210: Lyra Therapeutics
Lyra's lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra's XTreoT platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naive CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients. Currently, it is in Phase III stage of clinical trial evaluation to treat chronic rhinosinusitis.
TRL 1068: TRELLIS BIOSCIENCE
Trellis Bioscience has used its CellSpot Technology to identify a high-affinity and broad-spectrum native human antibody, TRL1068, which targets and disintegrates bacterial biofilm. Biofilm is a physiological factor promoting drug resistance in most clinically relevant multi-drug-resistant bacteria species, both gram positive and gram negative. Biofilm is also implicated as a factor promoting Alzheimer's pathogenesis. Currently, it is in Phase I stage of clinical trial evaluation to treat Chronic Rhinosinusitis with Nasal Polyps.
Sinusitis: Therapeutic Assessment
This segment of the report provides insights about the different Sinusitis drugs segregated based on following parameters that define the scope of the report.
Major Players in Sinusitis
There are approx. 15+ key companies which are developing the therapies for Sinusitis. The companies which have their Sinusitis drug candidates in the most advanced stage, i.e. phase III include, Lyra Therapeutics.
PhasesThe report covers around 20+ products under different phases of clinical development like
Sinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sinusitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sinusitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sinusitis drugs.
Sinusitis Report Insights
Sinusitis Report Assessment
Key Players
Key Products
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/v90ygq
View source version on businesswire.com:https://www.businesswire.com/news/home/20220912005605/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/12/2022 08:43 AM/DISC: 09/12/2022 08:43 AM
http://www.businesswire.com/news/home/20220912005605/en